Loading organizations...
§ Private Profile · Jerusalem, Yerushalayim, Israel
Develops ophthalmic medical devices for corneal edema and endothelial dysfunction, including Hyper-CL™ and synthetic endothelial implants.
Founded in 2011 by Nahum Ferera, Ofer Daphna, and Arie Marcovich, EyeYon Medical is an Israel-based medical device company developing innovative ophthalmic technologies to treat corneal edema and endothelial dysfunction. The organization's flagship products include Hyper-CL, a therapeutic contact lens with CE approval and FDA clearance, and EndoArt, a synthetic endothelial implant enabling minimally invasive surgery without human donor tissue. Operating within the broader ophthalmology sector, the firm targets surgeons and patients seeking advanced alternatives to traditional corneal transplant procedures. To support ongoing EndoArt clinical trials and commercialization efforts, the enterprise has raised $36 million in total venture capital funding, highlighted by a $25 million Series C financing round. This financial backing comes from a syndicate of institutional investors, including Rimonci Capital, Triventures, Pontifax, CR-CP Life Science Fund, and the Global Health Sciences Fund.
EyeYon has raised $31.5M across 2 funding rounds.
EyeYon has raised $31.5M in total across 2 funding rounds.
EyeYon has raised $31.5M across 2 funding rounds. Most recently, it raised $25.0M Series C in March 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 15, 2021 | $25M Series C | CR CP Life Science Fund | Brighton Park Capital, Diamond BioFund, Global Health Sciences Fund, Pontifax, Rimonci Capital, Triventures | Announced |
| Mar 21, 2017 | $6.5M Series B | Gauss Medical, Rimonci Capital | Pontifax, Triventures | Announced |
EyeYon has raised $31.5M in total across 2 funding rounds.
EyeYon's investors include CR-CP Life Science Fund, Brighton Park Capital, Diamond BioFund, Global Health Sciences Fund, Pontifax, Rimonci Capital, Triventures, Gauss Medical.